Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 010: Nivolumab dose-ranging in advanced RCC
NCT01354431Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2011
- Primary completion
- May 2013
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of nivolumab in renal cell carcinoma (RCC), sponsored by Bristol Myers Squibb. Started May 2011; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01354431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01354431.